Allergan receives European approval to market Ganfort for treatment of glaucoma

By Lisa Kerner

Erie, Pa., May 25 - Allergan, Inc. received the license from the European Commission to market the once-daily Ganfort, its Lumigan/timolol (bimatoprost 0.03%/timolol 0.5% ophthalmic solution) combination product for the treatment of glaucoma, in the European Union.

Ganfort is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.

Ganfort offers greater efficacy than monotherapy with either bimatoprost or timolol alone, according to a company news release.

In clinical trials, Ganfort had a superior tolerability profile, with 40% less hyperemia compared to bimatoprost monotherapy, the company said.

Allergan is a specialty pharmaceutical and medical device company located in Irvine, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.